Liquidia (LQDA) News
NASDAQ: LQDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
54.43-2.20 (-3.88%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LQDA news summary
We found 44 recent headlines mentioning Liquidia (LQDA): 1 in the past week and 15 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investing.com. For price context, LQDA is down 3.88% at $54.43. The most recent story, "Liquidia Corporation Appoints Russell Schundler as Chief Strategy Officer and General Counsel Effective November 16, 2026", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Liquidia headlines
- Liquidia Corporation Appoints Russell Schundler as Chief Strategy Officer and General Counsel Effective November 16, 2026On November 12, 2026, the Board of Directors of Liquidia Corporation appointed Russell Schundler as the Company’s Chief Strategy Officer and General Counsel, effective November 16, 2026. Mr.…Nasdaq
- LQDA Q3 Earnings Beat Estimates on Robust Yutrepia SalesLiquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.NasdaqLQDA, UTHR, COLL, AMRX
- Liquidia extends gains as Raymond James upgrades on Yutrepia launchSeeking Alpha
- Liquidia rises 7% after third-quarter results, litigation resolvedSeeking Alpha
- Liquidia (LQDA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Liquidia plans PH-ILD enrollment completion in 2028 with L606 NDA submission target in 2029Seeking Alpha
- Why is Liquidia stock gaining today?Investing.com
- Liquidia Corporation to Present at 2026 Jefferies Global Healthcare ConferenceMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and…GlobeNewswire
- Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15MSeeking Alpha
- Liquidia Corporation Reports Third Quarter 2026 Financial ResultsMORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…GlobeNewswire
- Liquidia Q3 2026 Earnings PreviewSeeking Alpha
- Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass EstimatesProtagonist Therapeutics (PTGX) delivered earnings and revenue surprises of +18.99% and +2.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for…NasdaqPTGX, LQDA
- Liquidia stock may move 6.5% on Nov. 10 earnings releaseInvesting.com
- Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…GlobeNewswire
- Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.NasdaqLQDA, UTHR, TGTX, IOVA
- LifeSci Capital Upgrades Liquidia to Outperform from Market PerformFintel reports that on October 14, 2026, LifeSci Capital upgraded their outlook for Liquidia (NASDAQCM:LQDA) (MUN:LT4) from Market Perform to Outperform.LifeSci Capital previously downgraded Liquidia…Nasdaq
- Liquidia soars 27% after settlement resolves litigationSeeking Alpha
- Notable Wednesday Option Activity: NN, VRT, LQDAAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NextNav Inc (Symbol: NN), where a total of 32,142 contracts have traded so far,…NasdaqNN, VRT, LQDA
- LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelLiquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.NasdaqLQDA, UTHR, AMRN, CORT
- Liquidia adds over 30% on United Thera. settlement; BTIG upgradesSeeking Alpha
- Liquidia And United Therapeutics Settle; But Only One Stock SkyrocketedLiquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market. The post Liquidia And United Therapeutics Settle; But Only One Stock…Investor's Business DailyLQDA, UTHR
- Premarket movers: Alibaba gains on new AI glasses; Liquidia rallies as legal easesInvesting.com
- Why is Liquidia stock surging today?Investing.com
- Liquidia shares surge to 5-month high premarket on United Therapeutics settlementInvesting.comUTHR, LQDA
- Liquidia Settles All Litigation With United Therapeutics; Shares Rise(RTTNews) - Liquidia Corp. (LQDA), a biopharmaceutical company, announced that it has entered into a global settlement agreement with United Therapeutics Corp. (UTHR) resolving all six pending…NasdaqLQDA, UTHR, ET
- Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battleSeeking AlphaLQDA, UTHR
- Liquidia stock surges 40% on $380.7M litigation settlement with UTHRInvesting.com
- Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHMORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with…GlobeNewswireLQDA, UTHR
- Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & KorsinskyLiquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate…PR Newswire
- Liquidia Stock Plunges 57% on UTHR Patent Litigation SetbackLQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.NasdaqLQDA, UTHR, INSM
- UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.NasdaqUTHR, ACIU, LQDA, PGEN
- United Therapeutics Prevails In Patent Litigation Against Liquidia(RTTNews) - United Therapeutics Corporation (UTHR) announced that the U.S. District Court for the District of Delaware ruled in its favor in patent litigation involving Liquidia Technologies'…NasdaqUTHR, LQDA
- United Therapeutics Wins Patent Case Against Liquidia(RTTNews) - Wednesday, United Therapeutics Corporation (UTHR) announced that the U.S. District Court for the District of Delaware ruled that Liquidia Technologies (LQDA) infringed claims 1 and 14 of…NasdaqUTHR, LQDA
- Can LQDA's Yutrepia Outpace Intensifying PAH Competition?Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.NasdaqLQDA, UTHR, INSM
- LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.NasdaqLQDA, UTHR, INSM
- Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.NasdaqLQDA, UTHR, INSM
- Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.NasdaqLQDA, UTHR, INSM
- Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.NasdaqINSM, LQDA
- Pre-Market Earnings Report for August 12, 2026 : AMCR, PFGC, TRMB, EAT, LQDA, GLBE, MRX, KTB, MSGE, EYE, TE, ITRNThe following companies are expected to report earnings prior to market open on 08/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Amcor plc (AMCR)is reporting for…NasdaqAMCR, PFGC, TRMB, EAT
- IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva UptakeImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.NasdaqIBRX, LQDA, HRMY
- Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in FocusKRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.NasdaqKRYS, NBIX, LQDA, HRMY
- MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y GrowthMadrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.NasdaqMDGL, LQDA, KNSA, HRMY
- Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock DownRDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.NasdaqRDY, NBIX, AMRN, LQDA
- Pre-Market Earnings Report for May 11, 2026 : CEG, B, KSPI, FOX, FOXA, MOS, KGS, RDNT, MNDY, LQDA, FSK, SDRLThe following companies are expected to report earnings prior to market open on 05/11/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Constellation Energy Corporation…NasdaqCEG, B, KSPI, FOX